Practical thinking on process development, regulatory strategy, and industrial scale-up — written for the people navigating these transitions.
The cost case for continuous manufacturing is usually pitched as "smaller footprint, less inventory." That’s true, but incomplete — the real shift is in where cost is incurred across the product lifecycle, not just at initial capex.
Read articleAdvanced Manufacturing Technology designation is one of the most underused fast-track pathways in FDA’s toolkit. Here’s what actually qualifies, what the designation changes procedurally, and where sponsors misjudge the timeline.
Read articleICH Q13 gets treated as a checklist, but it’s a lifecycle framework. Here’s what the guideline actually mandates versus what teams assume it does, and where that gap causes avoidable delays.
Read article